Ax-101 is an immune system modulatory compound, the First-in-Human Trial showed no adverse effects and efficacy in multiple cancers.

Value Focus

Ax-101 boosts the immune system so our immune system can destroy more cancer during this temporary blockade.

Proven Cancer Targets as a Single Agent

Lymphoma
Multiple Myeloma

Prospective Cancer Targets for Combination Therapy

Bladder
Colorectal
Non-Small Cell Lung
Hepatocellular
Triple-Negative Breast

Ax-101 activates and strengthens the immune system, extending its effectiveness to destroy cancer cells. In combination with Anti-PD-1 drugs destroys more cancer during the temporary blockade of the Anti-PD-1 drug. Ax-101 results in longer life and increased number of Complete Response (CR).

Improving Outcomes

In human trials as a single agent, Ax-101 shows safety, tumor shrinkage, restored DTH and measurable increased lethality to cancer.

Synergistic Effect

In animal trials as a combination therapy, Ax-101 has been proven effective against multiple cancers including bladder, colon, melanoma and lymphoma.

Favorable Risk vs. Benefit

Little apparent downside risk to Ax-101/ICI co-therapy, but significant upside potential for better outcomes, including cures.